S. Seagren

Publications58
h-index20
Citations3,567
Highly Influential Citations63
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Howell
  • 493 Publications • 21,550 Citations
  • J. Herndon
  • 272 Publications • 25,906 Citations
  • M. Green
  • 146 Publications • 15,694 Citations
  • R. Byhardt
  • 233 Publications • 15,155 Citations
  • Publications
  • Influence
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
TLDR
Long-term follow-up confirms that patients with stage III NSCLC who receive 5 weeks of chemotherapy with cisplatin and vinblastine before radiation therapy have a 4.1-month increase in median survival.
View on PubMed
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
TLDR
In patients with Stage III non-small-cell lung cancer, induction chemotherapy with cisplatin and vinblastine before radiation significantly improves median survival and doubles the number of long-term survivors, as compared with radiation therapy alone.
View on PubMed
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.
TLDR
Accelerated conformal radiotherapy was well tolerated in a high-risk population with clinical stage I NSCLC and is comparable to prospective reports of alternative therapies, including stereotactic body radiation therapy and limited resection, with less apparent severe toxicity.
View on PubMed
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage…
TLDR
The maximum-tolerated dose (MTD) of radiation (RT) in both standard daily and hyperfractionated-accelerated (HA) twice-daily RT schedules in concurrent chemoradiation was determined to be at least 70 Gy in 35 fractions over 7 weeks.
View on PubMed
Rapid superselective high‐dose cisplatin infusion for advanced head and neck malignancies
TLDR
Superselective rapid infusion of high‐dose cisplatin for patients with advanced head and neck malignancies is feasible, relatively nontoxic, and may have important applications in multimodality therapy, particularly for patientswith bulky primary disease.
View on Wiley
High dose rate intraluminal irradiation in recurrent endobronchial carcinoma.
TLDR
Palliative endobronchial high dose rate brachytherapy is a useful palliative modality in patients with recurrent endobronschial symptomatic carcinoma, and is concluded to be well tolerated with no toxicity.
View on PubMed
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer.
TLDR
This pharmacologic strategy permits the selective and rapid delivery of extremely high doses of DDP to head and neck carcinomas with minimal procedural complications, low systemic toxicity, and high tumor response rates.
View on PubMed
Infusional 5‐fluorouracil and x‐ray therapy for non‐resectable esophageal cancer
TLDR
Although the length of therapy is substantial (11 weeks), the program appears tolerable and is capable of inducing long‐term remissions and is currently being studied for dose escalation because neither local nor systemic side effects of a doselimiting nature have been observed at 20 mg/kg 5‐FU.
View on Wiley
The biology of head and neck cancer. Detection and control by parallel histologic sections.
TLDR
Using this principle for frozen-section evaluation, and reexcising further tissue as indicated, local disease was completely controlled in all 24 patients eligible for two-year follow-up.
View on PubMed
A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer.
View on PubMed
...
...